Literature DB >> 32525412

Three-Year Outcomes From the Harmony Native Outflow Tract Early Feasibility Study.

Lee N Benson1, Matthew J Gillespie2, Lisa Bergersen3, Sharon L Cheatham4, Kan N Hor4, Eric M Horlick5, Shicheng Weng6, Brian T McHenry6, Mark D Osten5, Andrew J Powell3, John P Cheatham4.   

Abstract

BACKGROUND: The Harmony transcatheter pulmonary valve (TPV) was designed for treatment of postoperative pulmonary valve regurgitation in patients with repaired right ventricular outflow tracts.
METHODS: The Native TPV EFS (Early Feasibility Study) is a prospective, multicenter, nonrandomized feasibility study. Three-year outcomes are reported.
RESULTS: Of 20 implanted patients, 17 completed 3-year follow-up (maximum: 4.1 years). There were no deaths and 2 early explants. One patient did not complete the 3-year visit. In patients with available 3-year echocardiographic data, 1 had a mild paravalvular leak and the rest had none/trace; 1 patient had mild pulmonary valve regurgitation and the remainder had none/trace. The 3-year mean right ventricular outflow tract echocardiographic gradient was 15.7±5.5 mm Hg. Radiographically, no late frame fractures or erosions were identified. At 2 years, 2 patients presented with an increased echocardiographic outflow gradient (1 mixed lesion with moderate/severe pulmonary valve regurgitation). Computed tomography scans identified neointimal tissue ingrowth within the stent frame in both patients, and they were treated successfully with a transcatheter valve-in-valve procedure (Melody TPV). Additional follow-up computed tomography scans performed at 3.2±0.5 years after implant were obtained in 16 patients and revealed luminal tissue thickening at the inflow and outflow portion of the frame with no significant alteration of the valve housing.
CONCLUSIONS: Three-year results from the Native TPV EFS revealed stable Harmony TPV device position, good valve function in most, and the absence of moderate/severe paravalvular leak and significant late frame fractures. Two patients developed significant neointimal proliferation requiring valve-in-valve treatment, while all others had no clinically significant right ventricular outflow tract obstruction. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01762124.

Entities:  

Keywords:  Tetralogy of Fallot; congenital heart disease; echocardiography; pulmonary valve; stent; tomography

Year:  2020        PMID: 32525412     DOI: 10.1161/CIRCINTERVENTIONS.119.008320

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  4 in total

1.  Choosing an appropriate size valve for transcatheter pulmonary valve implantation in a native right ventricle outflow tract.

Authors:  Muthukumaran C Sivaprakasam; J Raja Vijendra Reddy; Rajaguru Ganesan; Anuradha Sridhar; Neville Solomon; Musth Janeel Moosa; Zeeshan Sakina Lakhani; Sengottuvelu Gunasekaran
Journal:  Ann Pediatr Cardiol       Date:  2022-08-19

Review 2.  Transcatheter Device Therapy and the Integration of Advanced Imaging in Congenital Heart Disease.

Authors:  Abhay A Divekar; Yousef M Arar; Stephen Clark; Animesh Tandon; Thomas M Zellers; Surendranath R Veeram Reddy
Journal:  Children (Basel)       Date:  2022-04-02

Review 3.  The Future of Paediatric Heart Interventions: Where Will We Be in 2030?

Authors:  Tomohito Kogure; Shakeel A Qureshi
Journal:  Curr Cardiol Rep       Date:  2020-10-09       Impact factor: 2.931

4.  Early multicenter experience of a new balloon expandable MyVal transcatheter heart valve in dysfunctional stenosed right ventricular outflow tract conduits.

Authors:  Muthukumaran C Sivaprakasam; J Raja Vijendra Reddy; Sengottuvelu Gunasekaran; Kothandam Sivakumar; Sreeja Pavithran; Gopalavilasam Rajagopalan Rohitraj; M Jayranganath; Edwin Francis
Journal:  Ann Pediatr Cardiol       Date:  2021-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.